Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 292 participants.
Also called NCT01845831
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 292 participants
- Registry
-
NCT01845831
-
- Other papers using this trial's data
- Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01845831. Randomized; no masking; primary purpose treatment. Start 2013-08 (registry gives no type); primary completion 2016-04 (actual). Results posted on 2017-05-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Basal Bolus
- Intervention (Drug)
- Metformin and Sitagliptin
- Intervention (Drug)
- Glargine
- Intervention (Drug)
- Glargine 50%
- Intervention (Drug)
- Glargine 80%
- Lead sponsor
- Emory University
- Collaborator
- Merck Sharp & Dohme LLC
- Collaborator
- Temple University
- Collaborator
- University of Michigan
- Collaborator
- Ohio University
Record details
- Record id
cardio:ct-nct01845831- Content hash
f8f4a14dc5773c45e82604e504fdc386a32c8ae10087499b0fed3bb3aff4ae2d